Antipsychotic-induced weight gain sits at the intersection of two major health crises: the undertreatment of serious mental illness and the metabolic consequences that shorten lives. Patients with schizophrenia spectrum disorders already face dramatically elevated cardiovascular risk, and the medications that stabilize their condition often accelerate that risk through substantial weight gain. Establishing which pharmacological countermeasures actually work — and how they compare to one another — has long been a gap with real clinical consequences.
This systematic review and frequentist random-effects network meta-analysis, published in JAMA Psychiatry, synthesized evidence from randomized clinical trials identified through seven major databases up to December 2025, covering any pharmacological agent used to counteract antipsychotic-induced weight gain in adults with schizophrenia spectrum disorders. A network meta-analysis design was chosen specifically because it allows indirect comparisons across treatments that have never been tested head-to-head, generating a ranked hierarchy of efficacy. Evidence certainty was graded using the CINeMA framework, adding methodological rigor to the confidence estimates.
This research addresses a problem that has grown more urgent as second-generation antipsychotics — clozapine and olanzapine chief among them — became standard of care. Prior individual trials have examined metformin, topiramate, aripiprazole augmentation, and more recently GLP-1 receptor agonists, but no single review had integrated all these arms into a unified comparative framework until now. The network approach is particularly valuable here because psychiatrists rarely have access to direct comparative trial data when making prescribing decisions. Key limitations worth noting include heterogeneity in trial duration, baseline antipsychotic regimens, and outcome measurement, all of which can distort network estimates. Whether findings hold equally across clozapine-treated versus olanzapine-treated subgroups also remains a clinically important question. Still, as a methodological achievement — synthesizing the full pharmacological landscape in one coherent framework — this represents a meaningful advance over prior piecemeal evidence, likely to inform clinical guidelines for cardiometabolic management in psychiatric populations.